P/E ratio for Bionano Genomics (BNGO)
P/E ratio as of May 2024 (TTM): -0.0598
According to Bionano Genomics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.0597756. At the end of 2022 the company had a P/E ratio of -0.0986.
P/E ratio history for Bionano Genomics from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.0986 | -91.45% |
| 2021 | -1.15 | 99.12% |
| 2020 | -0.5792 | 974.59% |
| 2019 | -0.0539 | -75.8% |
| 2018 | -0.2227 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 PerkinElmer
PKI | 15.0 | -25,137.98% | 🇺🇸 USA |
 Quanterix QTRX | -9.81 | 16,307.88% | 🇺🇸 USA |
 Precipio PRPO | -0.7781 | 1,201.67% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.